主要文件

查看所有文档

1478800

USP

奥利司他

Name: 奥利司他
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

N-甲酰基-L-亮氨酸（1S）-1 - [[（2S，3S）-3-己基-4-氧代-2-氧杂环丁烷基]甲基]十二烷基酯, Ro-18-0647, （−）-四氢脂抑素

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₉H₅₃NO₅

化学文摘社编号:

96829-58-2

分子量:

495.73

NACRES:

NA.24

PubChem Substance ID:

329750618

UNSPSC Code:

41116107

MDL number:

MFCD05662360

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513), PNLIP(5406)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

溶液不完全澄清，小颗粒可能仍然悬浮。

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 奥利司他

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage.

James W Anderson

Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)

Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss

[The role of orlistat in the treatment of obesity].

György Paragh et al.

Orvosi hetilap, 146(11), 493-498 (2005-04-09)

The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need

Orlistat: a review of its use in the management of obesity.

Sheridan Henness et al.

Drugs, 66(12), 1625-1656 (2006-09-08)

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data

查看所有相关文献

全球贸易项目编号

货号	GTIN
1478800-200MG	04061838737694